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Abstract
DNA methylation is one of the most important epigenetic modifications in the regulation of
gene transcription. The current gold standard to study this modification is bisulfite sequenc-
ing. Although multiple commercial bisulfite treatment kits provide good conversion efficien-
cies, DNA loss and especially DNA fragmentation remain troublesome. This hampers DNA
methylation profiling of long DNA sequences. Here, we explored the performance of twelve
commercial bisulfite kits by an in-depth comparison of DNA fragmentation using gel electro-
phoresis, qPCR and digital PCR, DNA recovery by spectroscopic measurements and digital
PCR and conversion efficiency by next generation sequencing. The results show a clear
performance difference between the bisulfite kits, and depending on the specific goal of the
study, the most appropriate kit might differ. Moreover, we demonstrated that digital PCR is a
valuable method to monitor both DNA fragmentation as well as DNA recovery after bisulfite
treatment.
Introduction
DNA methylation (5-methylcytosine) is an epigenetic modification that is typically associated
with stable transcriptional silencing [1–4]. This modification plays an important role in several
biological processes associated with development and disease. Examples are cell differentia-
tion, regulation of gene expression, X-chromosome inactivation and genomic imprinting
[1,5,6]. In disease, DNA methylation is heavily involved in the development of genetic diseases,
carcinogenesis and silencing of intracellular viruses [7–17]. Consequently, DNA methylation
provides a promising diagnostic tool in medicine. Previous studies to understand the exact
role of DNA methylation in these disease settings have already resulted in several clinically val-
idated biomarkers (e.g. MGMT promoter methylation in patients with glioblastoma
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(PredictMDx, MDxHealth, Inc.); methylation of GSTP1, APC and RASSF1 genes for prostate
cancer testing (ConfirmMDx, MDxHealth, Inc.); methylation of PITX2 in Formalin-Fixed,
Paraffin-Embedded prostatectomy specimens for identifying patients who are at high risk to
suffer from prostate-specific antigen recurrence after radical prostatectomy; free-circulating
methylated SEPT9 gene copies in plasma as a screening biomarker for colorectal cancer;
SHOX2 DNA methylation as a plasma based biomarker for detection of lung cancer) [18–28].
The analysis of DNA methylation profiles is typically done through methylation-specific
PCR or bisulfite sequencing of DNA [29,30]. Bisulfite (HSO3
-) treatment is first described by
Frommer et al. [29] in 1992, and it is still the gold standard to analyze DNA methylation. This
chemical deaminates unmethylated cytosines (C), but not methylated cytosines (mC) to uracil
(U), enabling the analysis of the methylation profile through sequencing (Fig 1) [29,31].
Despite its wide use, bisulfite treatment has its disadvantages. Bisulfite conversion causes DNA
fragmentation, resulting in small sequences, typically smaller than 500 nucleotides (nt) [32–
35]. This is a result of the aggressive reaction condition of this conversion: pH 5 and tempera-
tures up to 90˚C [22,32,33,36]. The DNA fragmentation is mainly caused by depyrimidation
followed by alkali treatment, which leads to abasic sites, resulting by DNA cleavage of the
DNA phosphodiester bond (i.e. DNA degradation) [36]. Consequently, the analysis of the
methylation of large CpG-islands (CpGIs) is hampered [37].
It is assumed that longer reaction times and higher conversion temperatures cause relatively
more degradation [22,32,33]. However, if the temperature is too low or the reaction time is too
short, the conversion might be incomplete, resulting in an overestimation of the methylation
in the analyzed fragments. Therefore, the final conversion reaction has to be balanced out
between desired (conversion of Cs) and undesired effects (DNA fragmentation and inappro-
priate conversion (conversion of mC)) [22]. A number of studies have compared the perfor-
mance of different commercially available bisulfite kits, however, fragmentation or
degradation of the treated DNA was never the focus of these studies [22,39–41]. Yet, this issue
seems very important for some studies where the analysis of long fragments is necessary
[38,42]. For example, in the HIV genome, an important CpGI is situated in the 5’ Long Termi-
nal Repeat (LTR) region, and the genome is flanked by two identical LTRs [38]. Yet, mainly
the 5’ LTR is of interest, since this LTR contains the promoter region [10,11,38]. To determine
the methylation pattern of the promoter region of the HIV genome, we have to be able to dis-
criminate the 5’ from the 3’ LTR. This can only be performed by amplifying DNA fragments
covering the LTR as well as its a flanking region. As a result, DNA fragments have to be longer
than 600 nt, which is problematic for the analysis after bisulfite treatment. The issue of DNA
fragmentation has also been observed by Meissner et al. [42] in the development of an
approach for a large-scale high-resolution DNA methylation analysis termed reduced repre-
sentation bisulfite sequencing. In this protocol, DNA is digested, and fragments of 500–600 nt
are selected, and analyzed via bisulfite sequencing.
DNA yield analysis of bisulfite kits is typically performed with spectroscopic measurements
and DNA fragmentation analysis is performed by gel electrophoresis or with quantitative real-
time PCR (qPCR). In these cases, multiple analysis methods are necessary. Digital PCR
(dPCR) would enable us to assess the DNA yield and fragmentation with one single method.
This absolute quantification method bypasses bias from PCR inhibition since it provides an
end-point measurement of the positive signal enabling us to directly compare the DNA prod-
uct prior to bisulfite treatment with the product after treatment. Because of the absolute quan-
tification, it can replace multiple measurements with qubit, gel electrophoresis and qPCR.
In the current study, we provide a comprehensive procedure using state of the art technolo-
gies as dPCR to evaluate bisulfite treatment protocols by comparing twelve commercially avail-
able bisulfite kits, with focus on DNA fragmentation. The evaluation procedure consists of
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spectroscopic measurements and dPCR (DNA yield), gel electrophoresis, qPCR and dPCR
(DNA degradation) and next generation sequencing (conversion efficiency). We show that
dPCR is a valuable method to investigate the quality of bisulfite treated DNA. By using dPCR,
our workflow provides a method for differentiation of DNA loss from DNA fragmentation.
Results
Evaluation of DNA recovery
The absolute concentration of the DNA samples was measured on a Qubit 2.0 fluorometer
before bisulfite treatment (dsDNA assay) and after bisulfite treatment (ssDNA assay). The
starting DNA concentration was on average 136 ng/μl. The DNA recovery ranged from 26.6%
(Methyleasy (kit 12)) to 88.3% (EZ Gold (kit 5)) of the maximum theoretical concentration
based on the amount of input DNA (Fig 2, S1 and S2 Tables). Of note: different quantification
kits (Qubit dsDNA and ssDNA assays) were used before and after bisulfite treatment. The
quantification of these two assays was compared by measuring the DNA concentration before
and after heat denaturation of a DNA sample. This indicated a similar quantification for both
assays (data not shown). Therefore, only a relative comparison of the total DNA loss during
the bisulfite conversion of the different kits can be made by this analysis.
Evaluation of fragmentation
Gel electrophoresis. DNA fragmentation by the different bisulfite kits was visualized by
gel electrophoresis and Bioanalyzer analysis of the bisulfite treated DNA samples. These meth-
ods do not provide quantifiable data about the fragmentation, but provide a rough estimate to
compare the best and the worst kits. The untreated gDNA was used as a control showing a
clear band of minimally fragmented DNA after the DNA isolation procedure. A smear of
larger fragments was detected for the Epitect (kit 10) and CpGenome (kit 11) kits, indicating
that these are the least fragmenting kits (Table 1, S1 Fig).
Fig 1. Principle of bisulfite-mediated methylcytosine (mC) mapping. A: Deamination of cytosine (C) and mC. Sodium bisulfite deaminates C to uracil (U) (upper
row) and mC to thymine (T) (lower row). The rate of mC deamination is two orders of magnitude less than that of C. B: The mapping protocol: after bisulfite treatment,
mC will remain C where unmethylated C will be deaminated to U. During subsequent PCR amplification, the U deamination product templates adenine (A), which
then templates T, resulting in a C to T transition at unmethylated C. By sequencing, mC can be identified as bases that remained C after bisulfite treatment [38].
https://doi.org/10.1371/journal.pone.0199091.g001
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qPCR. The comparison of fragmentation of the kits by qPCR included different primer
pairs which were developed to amplify amplicons with lengths varying from 88 base pairs (bp)
to 476 bp. Overall, the smallest Cq values were found in the Epitect (kit 10) and CpGenome
(kit 11) indicating that the concentration of intact DNA strands of the analyzed length is the
highest in these kits (Fig 3).
Digital PCR. To test whether digital PCR (dPCR) can be used to assess both DNA recov-
ery as well as DNA fragmentation we used several primers pairs resulting in amplicons of dif-
ferent lengths (88 to 414 bp) to investigate the DNA recovery and the difference in
fragmentation between the twelve kits with dPCR. Since dPCR provides direct absolute quanti-
fication, the exact amount of DNA strands lost during conversion is measured. Overall, the
highest DNA concentrations were found in the Epitect (kit 10) and CpGenome (kit 11):
respectively 143.7 and 141.1 intact DNA strands of 88 nt; 16.5 and 17.8 intact DNA strands of
227 nt and 20.8 and 23.3 intact DNA strands of 414 nt per ng input DNA (Fig 4, Table 1 and
S4 Table).
Absolute quantification by dPCR before and after treatment showed a significant decrease
in number of intact copies in all kits when the length increased from 88 to 227 nt (on average
72.4% DNA lost vs 97.3% DNA lost, Wilcoxon rank sum test, p-value = 7.40e-07), but there
was no significant effect of the increase in length from 227 to 414 nt (on average 97.3% DNA
Fig 2. DNA recovery of the twelve bisulfite kits. DNA recovery is shown as percentages ± SD and is calculated by the ratio
of the measured output concentration of each bisulfite kit (Qubit ssDNA) to the maximal theoretical output concentration
based on the input in every kit (Qubit dsDNA). The labels in the figure refer to the kit numbers in Table 1.
https://doi.org/10.1371/journal.pone.0199091.g002
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lost vs. 96.1% DNA lost, Wilcoxon rank sum test, p-value = 0.478) (S5 Table). Between the dif-
ferent bisulfite kits, the Epitect (kit 10) retained 10.2% of the input DNA with length of 414 nt,
Table 1. Overview over the kits and their main characteristics and performance results.
Recovery Fragmentation Conversion
Kit Name Short name Conversion
temperature
(˚C) a
Conversion
time (min) a
Input
(ng
DNA)
Elution
volume
(μl)
Qubit
(ranking)
Gel
electrophoresis
(integrity: ++ =
high;— = low)
qPCR
(ranking)
dPCR
(ranking)
Conversion
efficiency
(% ± SD)
1 Bisulflash™ DNA
Modification Kit
(Epigentek, P-1026)
Bisulflash 95 20 350 15 9 - 11 10 Not Assayed
2 Bisulflash™ DNA
Bisulfite Conversion
Easy Kit (Epigentek,
P-1054)
Bisulflash Easy 80 45 135.8b 15 10 - 12 12 Not Assayed
3 Premium Bisulfite
Kit (Diagenode,
C02030030)
Premium 98 + 54 8 + 60 350 10 3 - 9 9 Not Assayed
4 Imprint1 DNA
Modification Kit
(Sigma-Aldrich,
MOD50)
Imprint 99 + 65 6 + 90 350 16 2 +/- 8 7 93.2 ± 9.3
5 EZ DNA
Methylation-Gold™
Kit (Zymo Research,
D5005)
EZ Gold 98 + 64 10 + 150 350 10 1 +/- 6 5 99.7 ± 0.1
6 EZ DNA
Methylation-
Lightning™ Kit
(Zymo Research,
D5030)
EZ Lightning 98 + 54 8 + 60 350 10 6 + 7 8 99.5 ± 0.1
7 Fast Bisulfite
Conversion Kit
(Abcam1,
ab1127127)
Fast 95 20 135.8b 15 5 - 10 11 Not Assayed
8 innuCONVERT
Bisulfite Basic kit
(Analytic Jena,
845-IC-1000008)
InnuCONVERT 85 45 1500 50 4 + 3 6 99.4 ± 0.4
9 Epitect1 Fast DNA
Bisulfite Kit
(Qiagen, 59824)
Epitect Fast 95 +60 10 + 20 1000 15 8 + 3 4 98.0 ± 2.2
10 Epitect1 Bisulfite
Kit (Qiagen, 59110)
Epitect 95 +60 15 + 285 1000 20 7 ++ 1 2 98.3 ± 0.7
11 CpGenome™ Turbo
Bisulfite
Modification Kit
(Merck Millipore,
S7847)
CpGenome 37 + 70 10 + 40 500 35 11 ++ 2 1 No data
12 Methyleasy™ Xceed
(Human Genetic
Signatures, ME001)
Methyleasy 37 + 80 15 + 45 2146b 55 12 + 5 3 97.7 ± 2.0
a If two values are given, the pre-incubation step (denaturation) was at another temperature than the incubation step. The first value indicates the pre-incubation
temperature or time, the second value indicates the incubation temperature or time.
b Recommended amount of input DNA in the protocol was given in volume. Since the recommended protocol was used, input varied for every donor sample. The input
in this table is the average input of the samples from the different donors.
https://doi.org/10.1371/journal.pone.0199091.t001
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while the Bisulflash easy (kit 2) retained only 0.2%. The same trend of DNA recovery (on aver-
age over all the kits) was found with the Qubit analysis (see S2 Fig).
Evaluation of conversion efficiency and inappropriate conversion
Since correct estimation of the methylation in the samples is the main goal after bisulfite treat-
ment, both appropriate conversion (i.e. conversion of C to U) and inappropriate conversion
(i.e. conversion of mC to thymine (T)) are crucial characteristics of a bisulfite kit. Therefore,
all kits were excluded from the comparison if the appropriate conversion was lower than 95%.
This conversion efficiency of the different bisulfite kits was analyzed by the amount of uncon-
verted Cs situated outside CpGs: in principle, 100% conversion of these Cs is expected, since
non-CpG Cs are seldom (<0.02%) methylated in human PBMCs [43–48]. Bisulfite treated
samples from one donor obtained with eight kits with best scores in the evaluation of the frag-
mentation and recovery were analyzed (see S6 Table). Two kits (Imprint (kit 4) and CpGe-
nome (kit 11)) showed lower conversion efficiencies for the non-CpG Cs in amplicon CFP2
(62 Cs, 2 CpG) compared to amplicon CCP3 (159 Cs, 32 CpG), indicating that the bisulfite
conversion was incomplete. However, the coverage of the sequencing reaction of CpGenome
(kit 11) was low (only 14 reads) (S6 Table). Consequently, these kits were excluded from the
final ranking. Moreover, a relative comparison of the inappropriate conversion was made
based on the methylation percentages obtained with the 34 CpGs analyzed. Gold (kit 5)
showed highest methylation (56.2% methylation), indicating that this kit shows the least inap-
propriate conversion, followed by Epitect (kit 10) (46.4% methylation) and Imprint (kit 4)
(42.5% methylation) (S6 Table and S1 Dataset). Of note: as a control, the variability of conver-
sion efficiency between different donors was analyzed. Therefore, the conversion efficiency of
samples from a second donor obtained with three kits (innuCONVERT (kit 8), Epitect (kit 10)
and Methyleasy (kit 12)) were analyzed and a low variability was observed: standard deviation
between 0.01 and 2.42% (data not shown).
Fig 3. Cq values ± SD of the smallest and the largest amplicons. The data used are the geometric means of the average values from the five donor samples as
shown in S3 Table. The data labels refer to the kit number as provided in Table 1.
https://doi.org/10.1371/journal.pone.0199091.g003
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Evaluation of effect of conversion time and temperature
To analyze the effect of increasing temperature and time of the bisulfite conversion on the
fragmentation, the degree of fragmentation of the different kits was linked with the time and
conversion temperature of each kit (Fig 5). The kits were ranked by fragmentation perfor-
mance based on the qPCR and dPCR results. No significant correlation between fragmentation
and time or temperature was found (Spearman’s rank correlation p-values: 0.521 (qPCR–tem-
perature), 0.155 (dPCR–temperature), 0.374 (qPCR–time) and 0.079 (dPCR–time)). To
exclusively analyze the effect of conversion temperature and time within a single kit, the frag-
mentation was compared by changing the conversion temperature and time in Epitect (kit 10).
Fig 4. Visual representation of the rankings of the dPCR experiments. Results are given as the geometric means of the average number of intact copies per ng
bisulfite treated (BT) DNA measured by dPCR ± SD of all the five donor samples as shown in S4 Table. The data labels refer to the kit number as provided in
Table 1.
https://doi.org/10.1371/journal.pone.0199091.g004
Evaluation of bisulfite kit performance using dPCR
PLOS ONE | https://doi.org/10.1371/journal.pone.0199091 June 14, 2018 7 / 17
We found no significant difference in fragmentation by these alterations (supplements: S7–S9
Tables and S3 and S4 Figs).
Discussion
The importance of DNA methylation in different biological processes and the need for an
easy-to-use technology have resulted in a wide range of commercially available bisulfite con-
version kits. To select the most appropriate bisulfite conversion kit for specific applications,
several parameters have to be taken into account. In the current study, we provide a compre-
hensive workflow for analyzing bisulfite kit performance by comparing twelve bisulfite kits
based on DNA recovery and DNA fragmentation. Since dPCR provides a direct absolute quan-
tification with minimal influence of variations in PCR efficiency [49], we can use one method
to directly compare samples before and after bisulfite conversion, enabling us to investigate
both DNA recovery and fragmentation with more ease and higher accuracy compared to clas-
sical methods. The present work shows the strength of dPCR for analysis of the quality of
bisulfite treated DNA.
The most essential parameter of a bisulfite kit is the conversion rate, for which appropriate
conversion should be maximized, and inappropriate conversion minimized. Our results
showed slightly higher estimation of the conversion rates for the cytosine containing (CC)
primers (or MethPrimers as called by Fuso et al. [50]) than for the cytosine free (CF) primers
(or Methylation Insensitive Primers (MIT) as in the manuscript of Fuso et al. [50]) in seven of
the eight samples, which was expected since the reactions with the CF primers amplify both
converted as unconverted DNA strands. Since non-CpG methylation is negligible in human
Fig 5. Effect of time and temperature. Effect of time and temperature of the conversion protocol on fragmentation between the different bisulfite conversion
kits. Labels refer to the kit numbers in Table 1. The upper panels (A-B) show the effect of different conversion temperatures between the kits measured by qPCR
(A) and dPCR (B). The lower panels (C-D) show the effect of different conversion times between the kits measured by qPCR (C) and dPCR (D). The values on
the x-axis are normalized to show the relative amount of fragmentation: 0 is least fragmenting and 1 is most fragmenting.
https://doi.org/10.1371/journal.pone.0199091.g005
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PBMCs, it is very unlikely that this bias is similar to the bias described in Fuso et al. [50] which
is due to methylated non-CpG Cs. During our comparison, CpGenome (kit 11) and Imprint
(kit 4) showed a large difference between the two primer types, indicating a low overall conver-
sion efficiency, and were therefore excluded from the comparison. However, CpGenome (kit
11) had no reliable coverage in the sequencing reaction, for which it also had to be excluded.
In other similar studies performed by Holmes et al. [22], Leontiou et al. [39], Izzi et al. [40]
and Bryzgunova et al. [41], the conversion efficiency was >95% for all the analyzed kits.
In the current comparison, we showed clear differences between the DNA recovery of the
bisulfite kits. This recovery is measured as the overall loss of DNA during the bisulfite treat-
ment, including DNA loss and fragmentation. Remarkably, the best recovery was found with
EZ Gold (kit 5), while EZ Lightning (kit 6) was ranked on the sixth place. Since both kits
appear to use the same DNA desulfonation and DNA clean up, the conversion buffers and
conditions may have impacted the DNA recovery. Our ranking of the recovery of the kits is in
accordance with previous comparative studies [22,39–41]. However, in these studies, DNA
recovery and fragmentation was never evaluated in depth: Leontiou et al. [39] evaluated both
DNA fragmentation and recovery by only measuring DNA concentration via spectroscopic
measurements, assuming that fragmentation leads to degraded DNA to such extent that it can-
not be analyzed by spectroscopic means. Consequently, our ranking for fragmentation is
completely different. Moreover, our findings show that their assumption may not hold for all
kits as we observed that kits with low fragmentation can have low recoveries (e.g. CpGenome
(kit 11) and Methyleasy (kit 12)).
To get a more detailed insight of how DNA is lost during bisulfite treatment, we used dPCR
to distinguish between DNA loss during clean-up and DNA fragmentation during conversion.
This method combines the insights obtained by spectroscopic measurements, gel electropho-
resis and qPCR to analyze the DNA recovery and the fragmentation. The exact amount of
DNA strands lost during the complete bisulfite treatment can be measured by comparing the
concentration before and after treatment. By quantifying the exact amount of DNA fragments
of different lengths, a fragmentation assessment can be made. The conclusions made by the
dPCR about the fragmentation and the DNA loss are in accordance with the results of the
Qubit, qPCR and gel electrophoresis, showing the strength of dPCR to combine recovery and
fragmentation analysis in a single platform. In this work, we did not evaluate whether the
DNA fragmentation and recovery are differently affected by the conversion step and the clean-
up step. Future work could help to decouple the effects of both separate parts of bisulfite treat-
ment on the resulting distribution of fragment sizes to completely understand the fragmenta-
tion kinetics and further optimize methylation kit performance.
In the current study, Epitect (kit 10) was selected as the most appropriate kit for methyla-
tion studies of long DNA fragments since this kit appears to induce least fragmentation. Its
conversion time of approximately 300 minutes is much longer than the average (80 minutes).
Of note: we could not exclude a potential bias in favor for Epitect (kit 10) since the DNA
extraction and bisulfite treatment kits are provided by Qiagen. Earlier studies by Grunau et al.,
Raizis et al. and Holmes et al. indicated that increased conversion temperature or prolonged
conversion time cause more fragmentation [22,32,33]. In the current study, we found no evi-
dence for a significant correlation between time and fragmentation or between temperature
and fragmentation for different kits. Interestingly, Grunau et al. found that fragmentation
mainly occurs during the first time period of the conversion (after 5 minutes, they observed
>90% DNA loss). This could explain the lack of effect on fragmentation by changing the con-
version protocol, and it could implicate that the first denaturation step is the most important
factor for the fragmentation during conversion. This step was not altered in the alternative
protocols of Epitect (kit 10), and could explain the lack of effect on the fragmentation of these
Evaluation of bisulfite kit performance using dPCR
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alterations. Although, this long incubation could potentially influence the conversion effi-
ciency and it does hamper high throughput methylation analysis with this kit [51]. For high
throughput studies, several kits provide a protocol with an incubation time less than 60 min-
utes. In analysis of shorter fragments, other factors might be decisive: if the amount of DNA is
limited, a high DNA recovery is needed, and thus EZ Gold (kit 5) appears to be a better option.
Next to this, a kit with a premade bisulfite mix (e.g. EZ Lightning (kit 6)) would fit better to
minimize pipetting variation and is ideal for high-throughput analyzes.
In conclusion, our study provides a comprehensive workflow to monitor bisulfite conver-
sion kits based on different parameters such as fragmentation, recovery or conversion effi-
ciency. By using dPCR to analyze the DNA recovery, we are able to analyze the DNA loss and
DNA fragmentation with one method. This comprehensive method enables researchers to
select the most appropriate kit, depending on the application in which DNA methylation
should be analyzed. This test could be important for every study, since the manufacturers can
improve the reagents and protocols of the kits over time. In this study, we limited the analysis
to standard conditions for the most kits and we only used genomic DNA obtained with one
method. Future studies could be performed with equalized DNA input, elution volume, con-
version conditions and DNA clean up in order to further understand the dynamics of the
bisulfite treatment, or use different types of input DNA in order to assess the influence of the
buffers of the extraction method on these parameters. There, our workflow would perfectly
suit to be used to monitor the effect of changes during optimizations of a bisulfite kit.
Material and methods
Human blood samples
Blood samples from healthy individuals were purchased from the Belgian Red Cross. All
donors signed a medical questionnaire containing an informed consent. This consent states
that the donated blood can be used for scientific and epidemiologic research if the blood was
refused for transfusion. The use of this blood was approved by the Ethical committee of Ghent
University Hospital with reference B670201317826.
DNA samples
Peripheral blood mononuclear cells (PBMCs) from five healthy human donors were isolated
using a lymphoprep centrifugation. DNA from aliquots of 107 PBMCs was isolated using the
DNeasy1 Blood & Tissue Kit (Qiagen, 69504). The DNA samples were all obtained on the
same moment, and they were immediately aliquoted into 20 aliquots to ensure the same
amount of freeze-thaw cycles for every sample. The DNA concentrations of the samples were
determined with the Qubit dsDNA BR (broad range) Assay Kit (Q32850, ThermoFisher Scien-
tific) on a Qubit 2.0 fluorometer, and the exact concentration was verified using the HS (high
sensitivity) Assay Kits (Q32851, ThermoFisher Scientific).
Bisulfite treatment
First analysis—Selection of the best kits. DNA from the five donor samples was bisulfite
treated with twelve different commercially available kits (Table 1). Every sample was converted
in duplicate, and after conversion, the duplicates were pooled to provide sufficient material for
subsequent testing. For all the kits, the standard protocols provided by the manufacturer with
the suggested input/elution volumes were used, and if not exactly provided, the average of the
indicated minimal and maximal input/elution were used.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0199091 June 14, 2018 10 / 17
Second analysis—Effect of time and temperature on fragmentation. Based on the first
analysis, the Epitect Bisulfite kit (Qiagen, 59110) was selected as the least fragmenting kit. Sub-
sequently, this kit was used to perform the protocol identically as described above on the five
PBMC samples, except for the conversion time or temperature which were modified (S7 and
S8 Tables). 1 μg of PBMC DNA from donor 3 (160 ng/μl gDNA) was used, and every conver-
sion was performed in duplicate. The converted DNA was eluted twice in 20 μl elution buffer,
and the duplicates were pooled.
DNA recovery
After conversion, 9 μl of every sample was diluted 1:2 in nuclease free H2O. From this 18 μl,
4 μl was used to determine the recovery after each conversion reaction. The Qubit ssDNA
Assay Kit (Q10212, ThermoFisher Scientific) was used on a Qubit 2.0 fluorometer to perform
duplicate spectrometric measurements on 2 μl of the diluted single-stranded, bisulfite-con-
verted DNA sample.
Fragmentation
Gel electrophoresis. Visualization of the fragmentation was performed by gel electropho-
resis using 40 ng converted DNA on an E-Gel1 EX Agarose Gel, 2% (Invitrogen, G401002).
Since the bisulfite treated DNA was single stranded, and the SYBR Safe dye in the gel only
binds dsDNA, a five-minute incubation on an ice bath enabled partial hybridization and visu-
alization of the DNA. The electrophoresis experiments were repeated on an Agilent 2100 Bioa-
nalyzer instrument with an Agilent RNA 6000 Pico Kit.
qPCR. To evaluate the amount of intact DNA copies of increasing length after bisulfite
treatment, the converted DNA was amplified using qPCR with 6 different primer pairs, result-
ing in amplicons of increasing length (88–476 bp). Two types of primers were used: cytosine
free (CF)-primers and cytosine containing (CC)-primers (S10 Table), which are similar to the
Methylation Independent Primers and MethPrimers as previously described by Fuso et al.
[50]. The CF-primers target genomic regions without C residues, with the same PCR efficiency
before and after treatment. The CC-primers target genomic regions that contain non-CpG C
residues. In the bisulfite converted samples, CF-primers amplify both converted and uncon-
verted DNA strands, but the CC-primers can only amplify converted DNA strands.
qPCR was performed using the LightCycler1 480 SYBR Green I Master PCR mix (Roche,
04707516001): 2.5 ng of bisulfite converted DNA was added to the qPCR mix containing
SYBR Green Mix (2x) and 500 nM forward and reverse primers, in a final volume of 20 μl.
PCR amplification reactions consisted of initial denaturation at 95˚C for 10 min, followed by
50 cycles (60 cycles for primer pair CCP1) of denaturation at 95˚C for 30 sec, annealing at spe-
cific temperature (see S10 Table) for 30 sec and elongation at 72˚C for 45 sec, and ended by a
melting curve analysis from 72˚C to 95˚C. Every qPCR was performed in triplicate on all five
bisulfite treated samples for each kit. The geometric mean of the Cq values among all repli-
cates, which corresponds with the amount of intact fragments, was used to rank all the kits. If
the melting curve analysis was not conclusive, amplicons were analyzed based on length, using
a HT DNA 5K chip (CLS760675, Perkin Elmer) on a Labchip1 GX (Perkin Elmer) (e.g. S5
and S6 Figs) [52].
Digital PCR. To eliminate the potential inhibitory effect of elution buffers or impurities
on the qPCR reaction, fragmentation was also analyzed using dPCR. Because of the ‘digital’
end-point measurement in dPCR, effects of PCR efficiencies are eliminated in the quantifica-
tion. Moreover, with dPCR, it is possible to perform a direct absolute quantification of intact
DNA copies in the PCR mix [49,53]. Similar as in the qPCR, several CF primers resulting in
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amplicons of different lengths (88 to 414 bp), were used to investigate the difference in frag-
mentation between the twelve kits.
2 μl DNA of all 60 bisulfite treated samples (1:2 diluted) was added to the dPCR mix con-
taining QX200 ddPCR EvaGreen Supermix (2x) (186–4033, Bio-Rad) with 100 nM forward
and reverse primers, in a final volume of 20 μl. PCR reactions consisted of initial denaturation
at 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 30 sec and annealing/elon-
gation at specific temperature (S10 Table) for 2 min, and ended with a signal stabilization at
4˚C for 5 min and 95˚C for 5 min. Each sample was analyzed in duplicate. Moreover, 8.65 μl of
untreated DNA samples from all donors was restricted with EcoRI enzyme (Promega, R6011)
according to the manufacturer’s instructions. 2μl of this restricted DNA was also used for
quantification using the same dPCR mix as the treated DNA samples. Based on the DNA con-
centration (absolute amount of intact copies per ng bisulfite treated input DNA), a ranking of
the 12 kits was made for each primer pair.
Conversion efficiency
The conversion efficiency was calculated as the amount of converted to non-converted non-
CpG Cs, which are usually not methylated in human PBMCs [43–48]. Almost all these Cs
should thus be converted during bisulfite treatment, providing us with a method to calculate
the conversion efficiency.
Based on the results from the DNA recovery and the fragmentation analysis, we selected
the eight least fragmenting kits for subsequent sequencing. We used qPCR amplicons of donor
2 generated with primer pairs CCP3 (149 Cs in amplicon, of which 32 CpG) and CFP2 (62 Cs
in amplicon, of which 2 CpG) for subsequent sequencing. The second primer pair can be used
to assess the overall conversion efficiency, while analysis with CCP3 can potentially result in
an overestimation of this efficiency. To assess the variability between the different donors, con-
verted DNA samples of a second donor (donor 3) obtained by three of the kits were also ana-
lyzed. The amplicons were purified with the High Pure PCR Product Purification Kit
(11732668001, Roche) and sequenced in a MiSeq sequencing system (Illumina). The sequenc-
ing reads were aligned using the Bismark package (version 0.10.1), and further analysis for the
conversion efficiency was done by the MethylKit package (version 0.9.5) in R.
Supporting information
S1 Table. Concentration of the DNA samples before bisulfite treatment. The concentration
of the untreated DNA samples obtained from PBMCs of five donors before bisulfite treatment
measured by Qubit dsDNA BR (broad range) Assay Kit.
(DOCX)
S2 Table. Amount of input DNA for bisulfite treatment and concentration of the DNA
samples after bisulfite treatment. Two aliquots of all five DNA samples were treated two
independent times, yielding in ten bisulfite treated samples, and subsequently, the duplicate
samples were pooled. The quantification measurements are done in duplicate with the Qubit
ssDNA Assay kit, and the data shown are averages ± SD of these ten concentrations.
(DOCX)
S3 Table. Cq values and ranking of the qPCR experiments from the six used primer pairs.
First the average of the three technical replicates was calculated for all five samples. The data
given is the geometric mean of the average values from the five donor samples. Genomic DNA
is the measurement of untreated DNA, which is only conducted for the cytosine free primers
since they have the same efficiency before and after treatment. The different kits are ranked by
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the Cq values for every primer pair (Rank in the table). Subsequently, the median of these
rankings is calculated to assess a final ranking. This is the ranking given in Table 1.
(DOCX)
S4 Table. Results and ranking of the dPCR experiments from the three primer pairs that
were used. First, the average of the two technical replicates was calculated and normalized to
the DNA input for all five samples. The data given is the geometric mean of the average values
from all five donor samples. The different kits are ranked by the amount of copies per ng bisul-
fite treated DNA for every primer pair (Rank in the table). Subsequently, the median of these
rankings is calculated to assess a final ranking. This is the final ranking given in Table 1.
(DOCX)
S5 Table. The percentages of overall DNA loss in the samples. The DNA loss is assessed by
dPCR before and after bisulfite treatment. This dPCR measures the intact copies of specific
lengths present in the samples. To obtain the averages given in the table, the average of the two
technical replicates was calculated both before and after bisulfite treatment. These averages
were used to calculate the average loss per kit of all the five donor samples. Subsequently, the
geometric means and standard deviations from these averages were calculated.
(DOCX)
S6 Table. Conversion efficiencies and overall methylation percentage for the different kits.
The data is obtained by sequencing of the 8 kits that performed best in the previous fragmenta-
tion assessments. One out of five donor samples was used, and two separate PCR products
were sequenced: amplicons CFP2 and CCP3. CFP2 (414 bp) counts 62 Cs, of which 2 CpGs;
CCP3 (476 bp) counts 159 Cs, of which 32 CpGs.
(DOCX)
S7 Table. Conversion protocol for different temperatures for Epitect (kit 10). The different
protocols followed a fixed time schedule as provided by the manual from the manufacturer.
Temperature protocol 3 is the same as the protocol provided by the manufacturer.
(DOCX)
S8 Table. Conversion protocol for different time schedules for Epitect (kit 10). The differ-
ent protocols always followed the temperature scheme as provided by the manual from the
manufacturer. Time protocol 3 is the same as the protocol provided by the manufacturer.
(DOCX)
S9 Table. Concentration after elution with Epitect (kit 10) with the different time and tem-
perature protocols as depicted in S7 and S8 Tables. In the end of the protocol, 2 elutions of
the same sample were performed (as recommended by the manufacturer to maximize DNA
yield). The data given is a single measurement of the donor used in these time and temperature
experiments.
(DOCX)
S10 Table. Primer sequences and annealing temperatures for qPCR and dPCR.
(DOCX)
S1 Fig. Bioanalyzer (upper plots) and gel electrophoresis (lower plots) analysis of the dif-
ferent kits. The plots shown in this supplement show the electrophoresis data of the five
donor samples.
(PDF)
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S2 Fig. Comparison of different recovery analyzes (red: Qubit vs black: dPCR). This recov-
ery is based on the amount of overall DNA loss in the samples as shown in S5 Table.
(TIF)
S3 Fig. qPCR analysis of the alternative protocols from the Epitect Bisulfite kit as shown in
S7 and S8 Tables. Upper panel: protocol changed in conversion temperature (S7 Table).
Lower panel: protocol changed in conversion time (S8 Table). Results are given as Cq
values ± SD.
(TIF)
S4 Fig. dPCR analysis of the alternative protocols from the Epitect Bisulfite kit as shown in
S7 and S8 Tables. Upper panel: protocol changed in conversion temperature (S7 Table).
Lower panel: protocol changed in conversion time (S8 Table). Results are given as number of
intact copies per ng bisulfite treated DNA measured by dPCR ± SD.
(TIF)
S5 Fig. Example of the melting curves (upper panel) and the Caliper LabChip GX results
(lower panel) after qPCR showing aspecific melting curves, but specific bands for the same
reaction: CCP1_after.
(TIF)
S6 Fig. Example of the melting curves (upper panel) and the Caliper LabChip GX results
(lower panel) after qPCR showing aspecific melting curves, but specific bands for the same
reaction: CCP2_after.
(TIF)
S1 Dataset. Sequencing data used for the conversion efficiency. Fastq files of the sequencing
data that were used for the conversion efficiency calculation.
(ZIP)
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